Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Pediatrix Medical (MD) Interest Expenses: 2009-2024

Historic Interest Expenses for Pediatrix Medical (MD) over the last 16 years, with FY2024 value amounting to $40.7 million.

  • Pediatrix Medical's Interest Expenses fell 1170.25% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.9 million, marking a year-over-year decrease of 1016.44%. This contributed to the annual value of $40.7 million for FY2024, which is 316.58% down from last year.
  • Latest data reveals that Pediatrix Medical reported Interest Expenses of $40.7 million as of FY2024, which was down 316.58% from $42.1 million recorded in FY2023.
  • In the past 5 years, Pediatrix Medical's Interest Expenses registered a high of $110.5 million during FY2020, and its lowest value of $39.7 million during FY2022.
  • In the last 5 years, Pediatrix Medical's Interest Expenses had a median value of $42.1 million in 2023 and averaged $60.3 million.
  • Per our database at Business Quant, Pediatrix Medical's Interest Expenses tumbled by 4223.83% in 2022 and then soared by 599.57% in 2023.
  • Over the past 5 years, Pediatrix Medical's Interest Expenses (Annual) stood at $110.5 million in 2020, then crashed by 37.8% to $68.7 million in 2021, then crashed by 42.24% to $39.7 million in 2022, then increased by 6.0% to $42.1 million in 2023, then dropped by 3.17% to $40.7 million in 2024.
  • Its last three reported values are $40.7 million in FY2024, $42.1 million for FY2023, and $39.7 million during FY2022.